Rating Change
HC Wainwright & Co. reiterated its Buy rating on Beam Therapeutics Inc. (NASDAQ:BEAM) on October 15, 2026.
reiterateNASDAQ:BEAM
HC Wainwright & Co. Reiterates Buy Rating on Beam Therapeutics Inc. (BEAM)
HC Wainwright & Co. reiterated its Buy rating on Beam Therapeutics Inc.
At publication ·
What changed
Beam Therapeutics Inc. (NASDAQ:BEAM) · reiterate
- Firm
- HC Wainwright & Co.
- Rating
- Buy to Buy
- Price at event
- $24.73
- Market capitalization
- $2.8B
At a glance
Key takeaways
- HC Wainwright & Co. reiterated a Buy rating on Beam Therapeutics (BEAM) on October 15, 2026, with the stock trading at $24.73 and a market cap of $2.8 billion.
Market Context
Beam Therapeutics Inc. operates in the Healthcare sector. The stock currently trades at $24.73 with a market capitalization of $2.8B. The stock has declined 6.8% over the past 52 weeks.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Beam Therapeutics Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Beam Therapeutics Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 15, 2026 | HC Wainwright & Co. | Buy | N/A |
| Oct 14, 2026 | Wedbush | Outperform | N/A |
| Sep 09, 2026 | Wedbush | Outperform | N/A |
| Aug 25, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jul 08, 2026 | B of A Securities | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View BEAM Stock Page
Frequently Asked Questions
What does the Buy rating mean for BEAM?
A rating of Buy from HC Wainwright & Co. reflects the analyst's outlook on Beam Therapeutics Inc. (NASDAQ:BEAM). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the BEAM forecast page.
